Zydus Lifesciences gets USFDA nod to mkt Scopolamine transdermal system
Scopolamine Transdermal System 1 mg/3 days had annual sales of USD 69.6 million in the US, the company said citing IQVIA MAT June 2024 data. Representative Picture
Zydus Lifesciences Ltd on Friday said it has received the final approval from the US Health regulator to market its Scopolamine transdermal system indicated to prevent nausea and vomiting under different circumstances.
The approval granted by the US Food and Drug Administration (USFDA) is to market the Scopolamine transdermal system of dosage 1 mg/3 days, Zydus Lifesciences said in a regulatory filing.
The Scopolamine transdermal system will be produced at the group’s transdermal manufacturing site at SEZ, Matoda, Ahmedabad, it added.
Scopolamine transdermal System is indicated to prevent nausea and vomiting after anaesthesia, narcotic pain medicines, and surgery. It is also used to prevent nausea and vomiting caused by motion sickness.
“This is the fifth abbreviated new drug application (ANDA) approval for Zydus in the transdermal portfolio, leveraging the group’s strengths in the manufacturing of complex drug device dosage forms,” the company said.
Scopolamine Transdermal System 1 mg/3 days had annual sales of USD 69.6 million in the US, the company said citing IQVIA MAT June 2024 data.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
First Published: Aug 30 2024 | 5:00 PM IST